Table 2.
Result from the multivariable logistic regression investigating the association between body mass index (BMI) categories and various clinical outcomes, with maximum follow-up 9 months and 15 months
| sample size, n | Maximum follow-up 9 months | Maximum follow-up 15 months | |||||
| n (%) events | OR (95% CI) | ORadj (95% CI) | N events | OR (95% CI) | ORadj (95% CI) | ||
| MDA | |||||||
| Normal weight | 306 | 45 (14.7) | 1 (ref.) | 1 (ref.) | 86 (28.1) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 21 (7.4) | 0.47 (0.27–0.82) | 0.52 (0.28–0.96) | 61 (21.4) | 0.67 (0.45–0.98) | 0.75 (0.48–1.15) |
| Obese | 183 | 12 (6.6) | 0.41 (0.21–0.80) | 0.44 (0.21–0.94) | 30 (16.4) | 0.50 (0.31–0.80) | 0.57 (0.34–0.96) |
| DAPSA-remission | |||||||
| Normal weight | 306 | 31 (10.1) | 1 (ref.) | 1 (ref.) | 67 (21.9) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 11 (3.9) | 0.35 (0.17–0.72) | 0.40 (0.18–0.88) | 31 (10.9) | 0.42 (0.26–0.68) | 0.50 (0.30–0.84) |
| Obese | 183 | 8 (4.4) | 0.41 (0.18–0.92) | 0.49 (0.20–1.18) | 17 (9.3) | 0.37 (0.21–0.67) | 0.47 (0.25–0.87) |
| DAPSA-remLDA | |||||||
| Normal weight | 306 | 47 (15.4) | 1 (ref.) | 1 (ref.) | 117 (38.2) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 37 (13.0) | 0.81 (0.51–1.30) | 0.88 (0.52–1.50) | 104 (36.5) | 0.91 (0.65–1.27) | 0.90 (0.62–1.31) |
| Obese | 183 | 22 (12.0) | 0.75 (0.43–1.29) | 0.75 (0.40–1.40) | 52 (28.4) | 0.64 (0.43–0.95) | 0.66 (0.42–1.03) |
| cDAPSA-remission | |||||||
| Normal weight | 306 | 36 (11.8) | 1 (ref.) | 1 (ref.) | 77 (25.2) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 22 (7.7) | 0.62 (0.35–1.09) | 0.70 (0.38–1.30) | 53 (18.6) | 0.65 (0.43–0.98) | 0.75 (0.48–1.16) |
| Obese | 183 | 12 (6.6) | 0.53 (0.27–1.06) | 0.64 (0.31–1.35) | 23 (12.6) | 0.43 (0.26–0.72) | 0.55 (0.32–0.95) |
| DAS28-remission | |||||||
| Normal weight | 306 | 68 (22.2) | 1 (ref.) | 1 (ref.) | 153 (50) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 64 (22.5) | 1.01 (0.68–1.49) | 0.91 (0.58–1.43) | 140 (49.1) | 0.91 (0.65–1.28) | 0.89 (0.61–1.3) |
| Obese | 183 | 29 (15.8) | 0.67 (0.41–1.08) | 0.50 (0.28–0.89) | 70 (38.3) | 0.62 (0.42–0.91) | 0.57 (0.36–0.88) |
| Treatment persistence at the end of follow-up | |||||||
| Normal weight | 306 | 204 (66.7) | 1 (ref.) | 1 (ref.) | 159 (52) | 1 (ref.) | 1 (ref.) |
| Overweight | 285 | 184 (64.6) | 0.86 (0.60–1.21) | 0.91 (0.60–1.36) | 148 (51.9) | 0.96 (0.69–1.34) | 0.97 (0.67–1.42) |
| Obese | 183 | 111 (60.7) | 0.77 (0.52–1.12) | 0.91 (0.57–1.44) | 81 (44.3) | 0.73 (0.51–1.07) | 0.87 (0.57–1.33) |
cDAPSA-remission, clinical Disease Activity for Psoriatic Arthritis (DAPSA) remission; DAPSA-remission, Disease Activity for Psoriatic Arthritis (DAPSA) remission; DAPSA-remLDA, DAPSA remission or low disease activity; DAS28-remission, 28-joint Disease Activity Score remission; MDA, Minimal Disease Activity; n, number; OR, odds ratio adjusting for: sex, age; ORadj, adjusting for: sex, age, high educational level, smoker, b/tsDMARDbiologic or targeted synthetic disease-modifying antirheumatic drug, csDMARDconventional synthetic disease-modifying antirheumatic drugs, corticosteroid.; ref., reference.